Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune system to fight cancer by enabling durable responses and preventing tumor recurrence
Our Approach
Proprietary Technologies
Immunetune has developed unique proprietary technologies enabling next-generation best-in-class DNA vaccines against cancer and infectious diseases.
Unique Differentiators
DNA-based vaccines offer distinct advantages for immunotherapy over other approaches such as peptide and RNA vaccines and cell therapies.
Company Highlights
About Us
Company Background
Immunetune is based in Leiden, the Netherlands, and is committed to develop best-in-class vaccines and bring them to patients with a sense of purpose and urgency.
News & Events
BIO-Europe, 25-28 October 2021
BIO-Europe, 25-28 October 2021 Sijme Zeilemaker, CEO of Immunetune, will be attending BIO-Europe, taking place October 25-28, 2021, in digital format. Feel free to reach out to us to set up a meeting and explore collaboration and investment opportunities. E-mail:...
World Vaccine Congress Europe, 19-21 October 2021
World Vaccine Congress Europe, 19-21 October 2021 Gerben Zondag, Founder & COO of Immunetune, will be attending the World Vaccine Congress Europe, taking place October 19-21, 2021, in Barcelona, Spain. Feel free to reach out to us to set up a meeting and explore...
Immunetune to Present Data on Neoantigen Cancer Vaccine Platform at SITC 2021
Immunetune to Present Data on Neoantigen Cancer Vaccine Platform at SITC 2021 LEIDEN, the Netherlands, October 1, 2021 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the...